Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 10/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.40 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.40 |
| ▸ | RARB | P10826 | 1/20 | 0.40 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.39 |
| ▸ | CFD | P00746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5569801 | 0.81 | VDR (0.53) | PPARAPPARGFFAR4FFAR1 | |
| SCHEMBL254346 | 0.77 | KAT8 (0.54) | PPARAPPARGKAT8RARB | |
| SCHEMBL5569783 | 0.76 | KAT8 (0.57) | PPARAPPARGKAT8RARB | |
| SCHEMBL5568404 | 0.76 | ALDH1A1 (0.41) | PPARAPPARGFFAR4FFAR1HPGD | |
| SCHEMBL5568363 | 0.75 | PPARA (0.44) | PPARAPPARGKAT8RARBCFD | |
| SCHEMBL334154 | 0.73 | FFAR4 (0.40) | FFAR4FFAR1HPGD | |
| SCHEMBL8159417 | 0.72 | KAT8 (0.62) | PPARAPPARGKAT8RARB | |
| SCHEMBL2687820 | 0.72 | KAT8 (0.62) | PPARAPPARGKAT8RARB | |
| SCHEMBL10397857 | 0.71 | PPARG (0.58) | PPARAPPARGHPGDPDE4APDE4B | |
| SCHEMBL7071495 | 0.71 | HDAC1 (0.50) | PPARAKAT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312249-B2 | Vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-12-25 | — | — | US | disclosed |
| EP-1537065-B1 | ANALOGUES OF VITAMIN D | GALDERMA RES & DEV (FR) | 2006-11-02 | — | — | EP | disclosed |
| US-20050182144-A1 | Novel vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-18 | — | — | US | disclosed |
| EP-1537065-A1 | ANALOGUES OF VITAMIN D | Galderma Research & Development, S.N.C. (FR) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004020379-A1 | ANALOGUES OF VITAMIN D | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182144-A1 | Novel vitamin D analogues | CYP24A1, CYP2R1, VDR | PPARA 134/4885PPARG 57/4885FFAR4 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.